Global Markets Direct’s, 'Dental Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Dental Pain. - A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dental Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Dental Pain - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dental Pain Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Dental Pain 7 Dental Pain Therapeutics under Development by Companies 9 Late Stage Products 10 Comparative Analysis 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Dental Pain Therapeutics - Products under Development by Companies 12 Companies Involved in Dental Pain Therapeutics Development 13 Eli Lilly and Company 13 Pfizer Inc. 14 Bayer AG 15 NeuroDiscovery Ltd 16 Array BioPharma Inc. 17 SCOLR Pharma, Inc. 18 Iroko Pharmaceuticals, LLC 19 Dental Pain - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 ARRY-797 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 NSL-101 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 PF-05089771 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 naproxen nanoformulation - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 LY-3023703 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 ibuprofen ER - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 (diphenhydramine hydrochloride + naproxen sodium) - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 Dental Pain Therapeutics - Drug Profile Updates 37 Dental Pain Therapeutics - Discontinued Products 38 Dental Pain Therapeutics - Dormant Products 39 Dental Pain - Product Development Milestones 41 Featured News and Press Releases 41 Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 41 Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables
Number of Products Under Development for Dental Pain, H2 2013 7 Products under Development for Dental Pain - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Late Stage Development, H2 2013 10 Comparative Analysis by Mid Clinical Stage Development, H2 2013 11 Products under Development by Companies, H2 2013 12 Eli Lilly and Company, H2 2013 13 Pfizer Inc., H2 2013 14 Bayer AG, H2 2013 15 NeuroDiscovery Ltd, H2 2013 16 Array BioPharma Inc., H2 2013 17 SCOLR Pharma, Inc., H2 2013 18 Iroko Pharmaceuticals, LLC, H2 2013 19 Assessment by Monotherapy Products, H2 2013 20 Assessment by Combination Products, H2 2013 21 Assessment by Stage and Route of Administration, H2 2013 23 Assessment by Stage and Molecule Type, H2 2013 25 Dental Pain Therapeutics - Drug Profile Updates 37 Dental Pain Therapeutics - Discontinued Products 38 Dental Pain Therapeutics - Dormant Products 39 Dental Pain Therapeutics - Dormant Products (Contd..1) 40
List of Figures
Number of Products under Development for Dental Pain, H2 2013 7 Products under Development for Dental Pain - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Late Stage Products, H2 2013 10 Mid Clinical Stage Products, H2 2013 11 Assessment by Monotherapy Products, H2 2013 20 Assessment by Combination Products, H2 2013 21 Assessment by Route of Administration, H2 2013 22 Assessment by Stage and Route of Administration, H2 2013 23 Assessment by Molecule Type, H2 2013 24 Assessment by Stage and Molecule Type, H2 2013 25
Eli Lilly and Company Pfizer Inc. Bayer AG NeuroDiscovery Ltd Array BioPharma Inc. SCOLR Pharma, Inc. Iroko Pharmaceuticals, LLC